Abstract：
This study aimed to evaluate the effect of sacubitril-valsartan (SV) on central apneas (CA) and obstructive apneas (OA) in patients with heart failure with reduced ejection fraction (HFrEF).
In patients with HFrEF, SV initiation was titrated to the highest tolerable dosage. Patients were evaluated with portable apnea monitoring, echocardiography, and cardiopulmonary exercise testing at baseline and 3 months later.
Of a total of 18 patients, 9 (50%) had OA, 7 (39%) had CA, and 2 (11%) had normal breathing. SV therapy was related to a reduction in NT-pro BNP and an improvement in LV function after 3 months. Portable apnea monitoring revealed a significant decrease of the respiratory event index (REI) after treatment with SV (20 ± 23 events/h to 7 ± 7 events/h, p = 0.003). When subgrouping according to type of apneas, REI, and time spent below 90% saturation (T90) decreased in patients with CA and OA (all p < 0.05).
In this prospective study, SV treatment for 3 months in patients with CA and OA is associated with a significant decrease in REI.
In patients with HFrEF, SV initiation was titrated to the highest tolerable dosage. Patients were evaluated with portable apnea monitoring, echocardiography, and cardiopulmonary exercise testing at baseline and 3 months later.
Of a total of 18 patients, 9 (50%) had OA, 7 (39%) had CA, and 2 (11%) had normal breathing. SV therapy was related to a reduction in NT-pro BNP and an improvement in LV function after 3 months. Portable apnea monitoring revealed a significant decrease of the respiratory event index (REI) after treatment with SV (20 ± 23 events/h to 7 ± 7 events/h, p = 0.003). When subgrouping according to type of apneas, REI, and time spent below 90% saturation (T90) decreased in patients with CA and OA (all p < 0.05).
In this prospective study, SV treatment for 3 months in patients with CA and OA is associated with a significant decrease in REI.
摘要：
目的：本研究旨在评估沙库巴曲缬沙坦（SV）对射血分数降低的心力衰竭患者的中枢性呼吸暂停（CA）和阻塞性呼吸暂停（OA）的影响。
方法：在HFrEF患者中，将SV起始滴定至最高耐受剂量。通过便携式呼吸暂停监测对患者进行评估，超声心动图,基线和3个月后的心肺运动试验。
结果：共有18名患者，9人(50%)患有OA，7人（39%）患有CA，2例（11%）呼吸正常。SV治疗与3个月后NT-proBNP降低和LV功能改善有关。便携式呼吸暂停监测显示，SV治疗后呼吸事件指数（REI）显着降低（20±23事件/h至7±7事件/h，p=0.003)。当根据呼吸暂停的类型进行分组时，REI,CA和OA患者在90％饱和度（T90）以下的时间减少（均p<0.05）。
结论：在这项前瞻性研究中，在CA和OA患者中，SV治疗3个月与REI的显着降低有关。
方法：在HFrEF患者中，将SV起始滴定至最高耐受剂量。通过便携式呼吸暂停监测对患者进行评估，超声心动图,基线和3个月后的心肺运动试验。
结果：共有18名患者，9人(50%)患有OA，7人（39%）患有CA，2例（11%）呼吸正常。SV治疗与3个月后NT-proBNP降低和LV功能改善有关。便携式呼吸暂停监测显示，SV治疗后呼吸事件指数（REI）显着降低（20±23事件/h至7±7事件/h，p=0.003)。当根据呼吸暂停的类型进行分组时，REI,CA和OA患者在90％饱和度（T90）以下的时间减少（均p<0.05）。
结论：在这项前瞻性研究中，在CA和OA患者中，SV治疗3个月与REI的显着降低有关。
